Piper Sandler started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued an overweight rating and a $48.00 price target on the stock.
AVTX has been the topic of several other research reports. Wedbush assumed coverage on Avalo Therapeutics in a report on Friday, February 21st. They set an "outperform" rating and a $18.00 price objective on the stock. BTIG Research initiated coverage on Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $35.33.
Read Our Latest Report on AVTX
Avalo Therapeutics Stock Performance
Shares of NASDAQ AVTX traded up $0.20 during midday trading on Friday, reaching $6.90. 24,907 shares of the stock were exchanged, compared to its average volume of 59,386. The stock has a 50 day moving average price of $7.55 and a 200-day moving average price of $9.25. Avalo Therapeutics has a 52-week low of $4.35 and a 52-week high of $34.46.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its holdings in shares of Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP acquired a new stake in Avalo Therapeutics during the 4th quarter worth approximately $114,000. Walleye Capital LLC purchased a new position in Avalo Therapeutics in the fourth quarter valued at approximately $145,000. Northern Trust Corp purchased a new position in Avalo Therapeutics in the fourth quarter valued at approximately $168,000. Finally, Bank of Montreal Can acquired a new position in Avalo Therapeutics during the fourth quarter valued at approximately $446,000. Institutional investors and hedge funds own 87.06% of the company's stock.
Avalo Therapeutics Company Profile
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Recommended Stories
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
